In press

2024-11-30

  Developments of ILP100-Oral was highlighted in an Editorial by American Journal of Gastrointestinal and Liver Physiology

"The implications of this study are substantial, extending beyond immediate therapeutic benefits to broader impacts on the field of colitis treatment and potentially other inflammatory diseases. The methodology used in this study could be adapted for other inflammatory diseases by engineering L. reuteri to express different therapeutic proteins. This broadens the potential applications of this approach beyond colitis" Our asset ILP100-Oral is currently at IND stage in development with: ✅ FDA pre-IND meeting completed allowing first-line-treatment ✅ SITU-GUT clinical phase 1/2a trial developed with KOLs for ICI-induced colitis stage 1 and 2 ✅CMC and GMP synergies with ILP100-Topical already in Phase 2 clinical developments with IND cleared for pivotal study ✅ Exceptional COGs, stability in room temperature ✅ Projections of blockbuster potential ➡️ The company seeking a suitable partner to accelerate the clinical development for this asset and share the expected joys of developing ground breaking research 💊 and the expected value generated💰 💰

2024-07-15

  American Physiological Society selects the publication by Öhnstedt et al 2024 describing the MOA and preclinical PoC for ILP100-Oral as a APSselect publication

American Journal of Physiology-Gastrointestinal and Liver Physiology, June 2024 issue Title: Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models Authors: Emelie Öhnstedt, Cristian Doñas, Kristel Parv, Yanhong Pang, Hava Lofton Tomenius, Macarena Carrasco López, Venkata Ram Gannavarapu, Jacueline Choi, Maria Ovezik, Peter Frank, Margareth Jorvid, Stefan Roos, Evelina Vågesjö, and Mia Phillipson